barasertib (AZD1152) / AstraZeneca - LARVOL DELTA

Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives. (PubMed, Front Oncol) - "Although clinical evaluation of these AURKB inhibitors such as barasertib (AZD1152) and AZD2811 remains limited, early findings support their potential efficacy, particularly in rationally designed combination regimens. This review describes the mechanistic interplay between HPV oncogenes and AURKB, highlights its role as a biomarker of aggressive disease, and critically assesses the therapeutic promise of AURKB inhibition. Finally, we outline future perspectives on integrating AURKB-targeted therapies into precision oncology for HPV-driven cervical cancer."

Journal • Review • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor • AURKB

Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma. (PubMed, Cell Oncol (Dordr)) - "This study identifies Aurora B as a therapeutically actionable vulnerability in HCC, whose inhibition induces senescence and enhances tumor immunogenicity. The combination of Aurora B inhibitor with anti-PD-1 therapy yields synergistic anti-tumor effects, supporting its potential as a promising strategy to improve immunotherapy outcomes in HCC."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • AURKB • CD8 • IFNG

Multitargeted kinase inhibitor LCI139 overcomes chemotherapy resistance in patient-derived non small cell lung cancer organoids by harnessing intrinsic and extrinsic apoptosis (AACR 2026) - "Treatments included LCI139 (0.25-1μM), chemotherapeutics (carboplatin, gemcitabine, pemetrexed, cisplatin), and single-agent inhibitors: PI3K (Buparlisib), CDK4/6 (Ribociclib), CDK9 (AZD4573), AURKA (Barasertib), AURKB (Alisertib). LCI139 demonstrates superior anti-tumor activity versus standard chemotherapeutics in resistant NSCLC through dual activation of intrinsic (cell cycle arrest-induced) and extrinsic (metabolic stress-induced) apoptotic pathways. Efficacy in both cell lines and PTOs validates this micro-physiological platform for drug development, supporting translational potential of multitargeted kinase inhibition for overcoming therapeutic resistance, as aligned with FDA guidance."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ANXA5 • AURKA • AURKB • CASP3 • CASP8 • CASP9 • CDK4 • CDK9

Evaluation of the effects of MDM2 inhibitor and epigenetic modifiers in combination with AURKB inhibitors for treating lung cancer (AACR 2025) - "We also examined the anti-cancer effects of RG-7388, SAHA, CM-272, and Barasertib (an AURKB inhibitor), in modulating cell cycle regulation...Our findings confirm that AURKB levels can be down-regulated by using the combination of MDM2 inhibitors and epigenetic regulators such as SAHA and CM-272. However, the therapeutic efficiency of these combinations needs to be verified using in vivo experimental models."

Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • ALDH1A1 • AURKB • BCL2L1 • CASP7 • CCNA2 • CDC25C • CDK4 • CDK6 • CDKN1A • GNRP • PARP1 • XIAP

Cell cycle inhibitors exhibit anti-tumor immunomodulatory roles through the HIF-1-DDX41 cytosolic DNA sensing pathway in HCC (AACR 2024) - "Anti-mitotic agents including Paclitaxel (microtubule stabilizer), Palbociclib (CDK4/6 inhibitor) and AZD1152 and GSK1070916 (Aurora Kinase B inhibitors) can also eliminate cancer cells via an alternative mechanism - the activation of STING signaling. In summary, this study exhibited the novel immune-mediated aspect of cell cycle inhibitors in suppressing tumor growth. Our data suggested the potential combination regimen of cell cycle inhibitors and currently available immunotherapy with promising result."

Immunomodulating • IO biomarker • Hepatocellular Cancer • Oncology • AURKB • DDX41 • HIF1A

Concurrent inhibition of the serine/threonine protein kinase AURKB and the fatty acid oxidation enzyme CPT1A demonstrates synthetic lethality in preclinical glioblastoma models (AACR 2025) - "Remarkably, the selective AURKB inhibitor barasertib was found to potently suppress the growth of established GBM cell lines, patient-derived xenograft models, and neurosphere cultures at low, nanomolar concentrations. Furthermore, the BH3-mimetic ABT263 was found to reduce the growth of GBM lines in the context of AURKB loss of function, likely due to the heightened dependence on mitochondrial metabolism. These findings uncover a previously unappreciated role for AURKB in regulating GBM metabolism and provide a strong rationale for further developing AURKB-targeted therapies, potentially in combination with metabolic inhibitors and BH3-mimetics, to improve clinical outcomes for patients with GBM."

Preclinical • Synthetic lethality • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • AURKB • CPT1A

Targeted Sensitization of Leukemic T-cells to Anticancer Drugs by SIRT1 Agonist SRT-1720. (PubMed, Anticancer Res) - "SRT-1720 induces oxidative stress and apoptosis in leukemic lymphocytes through SIRT1-independent pathway(s). In contrast, it enhances antioxidant defense in normal lymphocytes through a SIRT1-dependent pathway. These findings highlight the potential of SRT-1720 as an adjuvant to chemotherapy in T-ALL, particularly in drug combinations demonstrating strong synergism, which may allow dose reduction and decreased toxicity."

Journal • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • SIRT1

Combinatory inhibition of Aurora Kinases and EZH2 leads to a synergistic antitumor effect in Triple Negative Breast Cancer (SABCS 2025) - P2 | "Aurora kinase inhibitors, such as alisertib (MLN8237), have demonstrated early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer (NCT02860000)...Furthermore, RNA-seq analysis of the TNBC cells treated with Aurora Kinases inhibitors (AKi) Barasertib (AZD1152) and/or EZH2 PROTAC degrader MS177 reveals that AKi inhibits the expression of a panel of genes, which EZH2 degrader also regulates...To summarize, we discovered Aurora Kinases have a less-studied, non-canonical oncogenic function, which acts in parallel with the canonical cell division activity to produce more aggressive tumor metastasis phenotypes seen in TNBC. This non-canonical function highly depends on EZH2-mediated cancer cell apoptosis, proliferation, invasion, and metastasis, which differs from the well-known cell division function of Aurora Kinases, regulating chromosomal alignment, segregation, and cytokinesis during..."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AURKB • EZH2

AURKA Kinase Controls Erythroblast Enucleation Via Regulation of Centrosome Localization and ECT2 Degradation (ASH 2023) - "Treatment of erythroblasts with MLN8237 (Aliseritib, AURKA selective inhibitor), AZD1152(Barasertib, AURKB selective inhibitor), or AT9283 (AURKA and AURKB inhibitor) dramatically blocked enucleation in a dose-dependent manner. The translocation of AURKA, which is originally restricted to centrosome relied on γ-tubulin interaction during nuclear polarization, was to directly degrade ECT2 at the anterior end of the protrusive nucleus for final nuclear expulsion. Our findings reveal a previously unrecognized localization and role of Aurora kinases in terminal erythroid differentiation and provide new mechanistic insights into erythroblast enucleation."

AURKA • AURKB • ECT2 • PLK4

Long noncoding RNA TMPO-AS1 upregulates chromosomal passenger complex expression to promote cell proliferation in lung cancer via sponging microRNA let-7b-5p. (PubMed, Cell Div) - "Lung adenocarcinoma patients have poorer prognosis due to higher levels of CPCs, TMPO-AS1, and E2F1. A sponge complex between TMPO-AS1 and hsa-let-7b-5p may contribute to the tumor progression, and targeting CPCs with natural compounds could offer therapeutic potential. Highlights 1. The overexpression of chromosomal passenger complex genes, AURKB, BIRC5, CDCA8, and INCENP is significantly associated with poor prognosis in lung adenocarcinoma (LUAD), particularly among smokers. 2. The competing endogenous RNA (ceRNA) axis, which involves the long non-coding RNA TMPO-AS1 and the miRNA hsa-let-7b-5p, regulates the expression of these CPC genes. TMPO-AS1 shows a positive correlation with CPC genes, while hsa-let-7b-5p shows a negative correlation. 3. Survival analysis indicates that the combined expression of CPC genes, TMPO-AS1, hsa-let-7b-5p, and E2F1 may serve as a reliable prognostic biomarker panel for LUAD in smokers. 4. Hesperidin exhibits a strong binding affinity..."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AURKB • BIRC5 • CD4 • CDCA8 • E2F1 • MIRLET7B • TMPO-AS1

IN VITRO MODEL OF AURKB EXPRESSION LEVELS REGULATION MEDIATED BY SOFOSBUVIR TREATMENT (AASLD 2025) - " Cultures of Huh7 and Huh7.5 hepatoma cell lines were treated with SOF (C22H29N3FO9P) or daclatasvir (DCV) (BMS-790052) at different doses...All SOF-induced effects were reversed in the presence of AZD1152, an inhibitor of AURKB activity, confirming that they were exerted through the AURKB pathway... These results suggest that SOF can induce cell cycle modifications through AURKB activation in in vitro cell models. The effect of these changes in vivo (hepatitis C patients treated with SOF) should be analysed, taking into account that HCV eradication may induce an increase in AURKB per se, due to the inhibitory effect that the viral core protein exerts on AURKB activity."

Preclinical • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Solid Tumor • AURKB • DUSP1 • EGFR • PDGFRB

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities`. (PubMed, Sci Rep) - "CDK4/6i-resistant cell lines (MCF7rR, MCF7rA, MCF7rP, T47DrR, T47DrA, and T47DrP) were isolated and evaluated for their aggressive phenotypes, cross-resistance, transcriptomic changes, and sensitivity to volasertib (PLK1 inhibitor) and barasertib (AukB inhibitor). We conclude that cell cycle upregulation leading to G2/M progression is a key route for CDK4/6i resistance. AukB or PLK1 inhibitors that block G2/M phase could be a promising strategy."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CDK6 • CDKN2B • ER • HER-2 • TGFB1

Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat. (PubMed, Cancers (Basel)) - "Alisertib and barasertib emerge as potential in vitro candidates against MM, although further studies are needed to validate their efficacy and to find the best combinations with other molecules."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • CASP3

Discovery of the first-in-class Aurora B kinase selective degrader. (PubMed, Eur J Med Chem) - "Overall, compound 18 is a valuable chemical biology tool and a potential therapeutic. Our findings suggest that pharmacological degradation of AURKB could offer an alternative therapeutic approach for treating AURKB-dependent tumors."

Journal • Oncology • Targeted Protein Degradation • Von Hippel-Lindau Syndrome • AURKA • AURKB

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones. (PubMed, Exp Mol Med) - "Finally, our drug screening identified barasertib, an aurora kinase inhibitor, as a triple-combination candidate with epidermal growth factor receptor-tyrosine kinase inhibitors and XAV-939 for MYC+ cells. This study demonstrates the utility of longitudinal pharmacogenomic analysis to develop treatment strategies according to individual tumor evolution type. The study underscores the importance of integrating genomic and pharmacogenomic profiling in clinical practice to tailor treatments according to tumor evolution type."

Biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR • TP53

The current landscape of quinazoline derivatives with in vivo anticancer therapeutic potential-part I. (PubMed, Future Med Chem) - "Moreover, several quinazoline hybrids, exemplified by Fruquintinib (quinazoline-benzofuran hybrid) and Barasertib (quinazoline-pyrazole hybrid), have already been applied in clinics for cancer therapy, indicating that the rational design of quinazoline hybrids may provide valuable chemotherapeutics for cancer therapy. This review outlines the current scenario of the in vivo anticancer therapeutic potential of quinazoline hybrids, together with modes of action, toxicity, and pharmacokinetic properties, developed from 2015 onwards, aiming to provide promising candidates for further preclinical/clinical evaluations and to facilitate further rational design."

Journal • Preclinical • Review • Oncology

Common Regulatory Mechanisms Mediated by Cuproptosis Genes in Inflammatory Bowel Disease and Major Depressive Disorder. (PubMed, Genes (Basel)) - "These findings have substantially enhanced our understanding of the similarities and differences in the regulatory mechanisms of CRGs within brain-gut axis diseases. Key biomarkers have been identified, and potential therapeutic drugs have been predicted to effectively target IBD and MDD."

Journal • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Major Depressive Disorder • Mood Disorders • Psychiatry • CDKN2A • DLAT • LIAS • SLC31A1

Co-inhibition of Aurora kinase B and SUV4-20H induces synthetic lethality in Wild-type p53 deficient cancer cells. (PubMed, Mol Cancer Ther) - "Barasertib (AZD2811) targets the mitotic kinase Aurora B (AURKB) and is in current clinical trials for various cancers. Lastly, we found in two different p53 mutated cell line tumor models that barasertib plus A196 has greater anti-tumor activity than either single agent. Our results suggest co-targeting of AURKB and SUV4-20H1/2 could be effective against p53-mutated or deficient cancers, including TNBCs in which approximately 80% of cases are p53 mutated."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AURKB • TP53

Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies. (PubMed, Cell Rep Med) - "Finally, we demonstrate that the combination of barasertib with a p21 attenuator is more effective in reducing vascular remodeling than either drug alone. These findings provide insight into strategies for therapeutic manipulation."

Journal • Preclinical • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • AURKB • CDKN1A

Structural characterization of Aurora kinase B modulation by Epigallocatechin gallate: Insights from docking and dynamics simulations. (PubMed, J Mol Graph Model) - "Synthetic inhibitors like AZD1152 and ZM447439 show selectivity for AURKB but often lack specificity due to high homology within the aurora kinase family. The study also noted transitions in the overall protein secondary structures, such as turn to coil, coil to sheet, and coil to helix, contributing to a stable structure upon EGCG binding. These findings highlight the complex interplay between EGCG and AURKB, providing insights into the conformational dynamics and structural alterations induced by this interaction, which has implications for reducing glioma cell chemosensitivity to therapeutic drugs."

Journal • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • AURKB • EGFR

Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trials. (PubMed, EBioMedicine) - "This study presents a drug development strategy that integrates clinically validated LN therapies with drug repurposing approaches. This strategy could accelerate drug development and clinical translation processes for LN."

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • AURKB

Evaluation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal novel therapeutic opportunities in ER+/HER2- breast cancers (SABCS 2024) - "CDK4/6i resistant and sensitive cells were evaluated for spheroid forming ability, cell cycle progression, apoptosis, cross resistance to other CDK4/6i, whole genome RNA sequencing, and cisplatin/volasertib (PLK1 inhibitor)/barasertib (Arora kinase B inhibitor) sensitivity. In ER+/ HER2− BCs, pathways to resistance to CDK4/6i therapy are complex and diverse. PLK1 or Aurora Kinase B targeting could be an attractive therapeutic strategy in certain CDK4/6i resistant ER+ BCs."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • AURKB • CDK6 • ER • HER-2 • TGFB1

Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer: A Plausible Alliance to Enhance Cell Death. (PubMed, Cancers (Basel)) - " We analyzed the effects of co-treating OSCC cells with small molecules targeting MPS-1 (BAY1217389), Aurora-B (Barasertib), or KSP (Ispinesib), alongside Cetuximab. Additionally, we examined EGFR, MPS-1, Aurora-B, and KSP expression in OSCC patient samples, revealing their clinicopathologic significance. This combinatorial approach suggests a promising strategy to improve treatment outcomes in OSCC."

Journal • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • EGFR

Identification of Vesicle-Mediated Transport-Related Genes for Predicting Prognosis, Immunotherapy Response, and Drug Screening in Cervical Cancer. (PubMed, Immun Inflamm Dis) - "The VMTRG-based prognostic model demonstrates reliable clinical prognostic value and enhances understanding of vesicle-mediated transport mechanisms in CC."

Biomarker • IO biomarker • Journal • Cervical Cancer • Oncology • Solid Tumor

AZD1152: Repurposing for Treatment of Lupus Nephritis Driven by the Results of Clinical Trials (KIDNEY WEEK 2024) - "Combination therapy consisting of mycophenolate mofetil ,tacrolimus and glucocorticoid achieved a 20% higher CR than conventional therapy. This is the first study to illustrate the therapeutic effect of AZD1152 in SLE and renal injury. The comparable efficacy of AZD1152 to combination regime means it is able to further reduce the side effects of drug combination. Our study also revealed the potential of AURKB as a biomarker to predict LN disease activity."

Clinical • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • AURKB